news

Lundbeck to present new Brintellix® data at the Annual Society of Clinical Psychopharmacology (ASCP) Meeting

Posted: 29 May 2014 | | No comments yet

Data highlights safety and efficacy profile of Brintellix, including difficult to treat patients and special patient populations…

H. Lundbeck A/S Logo 60x60

H. Lundbeck A/S (Lundbeck) announced today that seven posters highlighting scientific data and clinical research will be presented at the upcoming Annual Society of Clinical Psychopharmacology (ASCP) held in Hollywood, Florida, from June 16-19, 2014. These data represent Lundbeck’s ongoing commitment to clinical advances and are an important step in our pursuit of improving patients’ functional outcome in Major Depressive Disorder (MDD). 

The ASCP scientific committee has nominated, “The Effect of Vortioxetine on Sexual Dysfunction During the Treatment of Adults With Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD),” as a best poster and it will appear in the online 2014 ASCP Poster Session.

Brintellix® was discovered and developed in Lundbeck Research Laboratories. Brintellix® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorders in adults and by the European Commission for the treatment of adults with Major Depressive Episodes, commonly referred to as depression. More recently, the Australian Therapeutic Goods Administration (TGA) approved Brintellix® for the treatment Major Depressive Disorders in April 2014.

Related organisations